J&J Just Shrugged Off the Government's Drug Pricing Hammer
The Trump administration's Most Favored Nation drug pricing policy was supposed to squeeze Big Pharma's margins. J&J just raised its 2026 forecast anyway, and Wall Street isn't worried. Here's why the pricing hammer may have actually helped the giants.
The U.S. government told pharma companies to slash their prices. Johnson & Johnson's response? A raised forecast and a confident grin.
That's the story coming out of J&J's 2026 guidance updates, where the company essentially told investors that the Most Favored Nation (MFN) drug pricing policy, the Trump administration's biggest swing at pharmaceutical costs, is a speed bump, not a roadblock. And Wall Street is buying it.
The Policy That Was Supposed to Change Everything
Let's rewind. In May 2025, the White House signed an executive order called "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients." The idea is simple: U.S. drug prices should match the lowest price a company charges in any comparable developed country. If Danes pay $50 for a drug that costs Americans $300, well, Americans should get the Danish price.
The Department of Health and Human Services defined "comparable" as any OECD country with a GDP per capita at least 60% of the U.S. figure. Manufacturers were given 30 days to hear their price targets, with the threat of formal rulemaking if they didn't play ball.
Sounds like a big deal, right? On paper, it is. The policy covers Medicaid patients and a direct-to-consumer channel called TrumpRx, and it's been positioned as extending to commercial markets over time. By January 2026, 16 major pharma companies had signed voluntary MFN agreements, including J&J, Pfizer, Merck, and AbbVie.
But here's what actually happened: J&J absorbed the hit and kept growing.
The Numbers Don't Lie (and They Look Pretty Good)
J&J's spring 2026 guidance update told a surprisingly upbeat story. The company raised its full-year revenue forecast to about $100.8 billion at the midpoint, representing roughly 7% reported sales growth. Adjusted earnings per share guidance climbed to $11.45 to $11.65, implying nearly 6% profit growth.
Management was transparent about the cost. They said MFN-related pricing concessions would create "hundreds of millions" of dollars in revenue headwind during 2026. That's real money. But it's already baked into those numbers, and the numbers still came in above Wall Street's prior expectations.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Think of it like a restaurant raising menu prices after their rent went up. The rent increase hurts, sure. But if the restaurant is also selling more meals, expanding to new locations, and cutting waste in the kitchen, the higher rent becomes just another line item, not a crisis.
J&J is selling a lot more meals.
What's Actually Driving the Growth
The real story isn't about what's dragging J&J down; it's about what's pulling it forward. The company's oncology franchise is on fire, and not in the "everything is burning" way.
Darzalex, J&J's blockbuster multiple myeloma drug, posted operational growth above 20% year-over-year in early 2026, with quarterly sales hitting $4 billion. That's a single drug generating more revenue per quarter than most biotech companies produce in a year. Alongside it, newer blood cancer treatments like Carvykti (a CAR-T therapy), Tecvayli, and Talvey are building what amounts to a myeloma empire.
On the immunology side, Tremfya is growing fast enough to help offset the steep decline in Stelara sales. Stelara, once J&J's crown jewel, is getting hammered by biosimilar competition and is one of the few J&J drugs actually subject to Medicare price negotiation in 2026. Management has been planning for this cliff for years, and the handoff to Tremfya appears to be working.
Then there's the CNS play. J&J's acquisition of Intra-Cellular Therapeutics brought Caplyta, a growing treatment for bipolar disorder and schizophrenia, into the fold. Combined with Spravato for treatment-resistant depression, J&J now has a legitimate neuropsychiatry platform that barely existed a few years ago.
And we haven't even touched MedTech. The integration of Abiomed (heart pumps) and Shockwave Medical (a clever device that uses shockwaves to break up calcified arteries) has created a cardiovascular growth engine. Meanwhile, J&J's robotic surgery platform, Ottava, has been submitted to the FDA for review. If approved, it would plant J&J's flag in one of the fastest-growing segments of surgical technology.
Management claims the company has 28 "priority platforms" each capable of generating more than $1 billion in peak sales. Even if half of those hit, that's a staggering amount of diversified growth.
Wall Street's Verdict: Move Along, Nothing to See Here
Analysts have largely sided with J&J's "manageable headwind" framing. The consensus view is that MFN costs are real but smaller than investors initially feared. When J&J's guidance came in above expectations despite explicitly including hundreds of millions in pricing concessions, it effectively closed the gap between Wall Street's worst-case fears and reality.
Some firms remain cautious, but their concerns tend to center on talc litigation risk and general regulatory uncertainty rather than MFN specifically. RBC analyst Trung Huynh has flagged headline risk from ongoing Medicare negotiation efforts, but even he expects the practical impact to be limited by legal challenges, exemptions, and portfolio diversification.
The broader analyst take is telling: MFN-style deals amount to "pandering on carefully selected drugs" with negligible effects on net profits for large pharma. The companies that signed these agreements got something valuable in return: three-year exemptions from tariffs and future pricing mandates. For a company like J&J that imports MedTech components globally, tariff relief alone is worth a fortune (the company estimated roughly $500 million in MedTech tariff costs for 2026).
The Bigger Picture: Big Pharma Wins Again
Zoom out, and a pattern emerges. MFN was supposed to be the government's power move against pharmaceutical pricing. Instead, it may have strengthened the largest companies at the expense of smaller ones.
All four mega-cap pharma players (J&J, Pfizer, Merck, AbbVie) signed MFN deals and received tariff immunity in return. They have the scale to absorb targeted price cuts on specific drugs. They have diversified portfolios that limit exposure to any single product. And they have the negotiating leverage to shape favorable deal terms.
Smaller, R&D-dependent biotech firms? They don't have those luxuries. The compliance burden and pricing constraints hit them disproportionately harder. It's the regulatory equivalent of a weight class mismatch.
Among the big four, J&J arguably sits in the best position. It signed later than Pfizer (which went first and set the template), giving it time to negotiate better terms. Its diversification across pharma and MedTech dilutes the impact. And unlike AbbVie, which had to absorb more visible price cuts on Humira under its MFN agreement, J&J's concessions have been quieter and less concentrated.
So What's the Catch?
The obvious risk is that MFN is just the opening act. If the policy expands beyond Medicaid and TrumpRx into broader commercial and Medicare markets, the math changes significantly. Right now, MFN covers a relatively narrow slice of total U.S. drug sales. Widen that slice, and even J&J's diversification can't fully insulate it.
There's also the Stelara overhang. Biosimilar erosion contributed roughly 900 to 1,000 basis points of drag on Innovative Medicine growth in early 2026. The replacement strategy (Tremfya, oncology expansion, CNS launches) needs to keep executing quarter after quarter. One stumble, and the narrative shifts fast.
But for now, J&J is doing something rare in pharma: growing through a pricing storm while actually raising guidance. The government swung its biggest hammer, and J&J barely flinched.
Funding & Financings
5 min read
The Gene Editing Company That Wants to Replace Your Cholesterol Meds
A gene editing startup co-founded by a Nobel laureate just filed to go public, and it's not chasing rare diseases. Scribe Therapeutics wants to use CRISPR to replace your daily cholesterol pills with a single dose that silences the genes behind heart disease.
